Literature DB >> 9295031

Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults.

V Udhayakumar1, J M Ongecha, Y P Shi, M Aidoo, A S Orago, A J Oloo, W A Hawley, B L Nahlen, S L Hoffman, W R Weiss, A A Lal.   

Abstract

In this study, we have investigated the extent of natural polymorphism in the CD8+ cytotoxic T lymphocyte (CTL) determinant (amino acids 368-390) of circumsporozoite (CS) protein of Plasmodium falciparum field isolates from a holoendemic region of Kenya, and determined how this variation affects the CTL reactivities in clinically immune adults and binding specificities to human histocompatibility leukocyte antigen (HLA)-B35. Among the eight variant sequences that were found in this region, four were new and not seen in parasites from other geographical regions. When synthetic peptides corresponding to the eight variants were used to test the presence of CTL response in different donors, a different spectrum of CTL reactivity to these variants was noticed. While CTL from some donors recognized the P1 sequence (the most prevalent type of sequence) but not P8 (another major variant), other donors showed a reverse pattern of reactivity. Although none of the donors was able to recognize all the variants, CTL responses to all the eight variant sequences were found in this population. An octamer peptide with P1 sequence KPKDELDY in this polymorphic determinant was known to bind HLA-B35. When we tested the effect of natural variation in this octamer sequence on HLA-B35 binding, it became evident that SP13 with D --> N substitution retained its binding specificity to HLA-B35. On the other hand, the SP12 octamer sequence which had two substitutions did not bind HLA-B35. The most interesting finding was the observation that a D --> G substitution at position 374 rescued the binding ability of SP14, which otherwise could not bind to this HLA molecule due to E --> Q amino acid substitution at position 372. To our knowledge, this is the first demonstration showing that a natural polymorphism can rescue the binding specificity to an HLA-class I molecule that was lost due to another natural amino acid substitution. Altogether, these results demonstrate that natural polymorphism in the CS protein affects both the CTL reactivity and the ability to bind to HLA-B35.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9295031     DOI: 10.1002/eji.1830270819

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

1.  A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.

Authors:  I S Soares; J W Barnwell; M U Ferreira; M Gomes Da Cunha; J P Laurino; B A Castilho; M M Rodrigues
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

2.  A Prime/Boost PfCS14KM/MVA-sPfCSM Vaccination Protocol Generates Robust CD8+ T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria.

Authors:  Aneesh Vijayan; Ernesto Mejías-Pérez; Diego A Espinosa; Suresh C Raman; Carlos Oscar S Sorzano; Fidel Zavala; Mariano Esteban
Journal:  Clin Vaccine Immunol       Date:  2017-05-05

3.  Sequence variation in the T-cell epitopes of the Plasmodium falciparum circumsporozoite protein among field isolates is temporally stable: a 5-year longitudinal study in southern Vietnam.

Authors:  Amadu Jalloh; Huynh van Thien; Marcelo U Ferreira; Jun Ohashi; Hiroyuki Matsuoka; Toshio Kanbe; Akihiko Kikuchi; Fumihiko Kawamoto
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

4.  Influence of age and HLA type on interferon-gamma (IFN-gamma) responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1 (LSA-1).

Authors:  K Bucci; W Kastens; M R Hollingdale; A Shankar; M P Alpers; C L King; J W Kazura
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

5.  Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine.

Authors:  Y P Shi; S E Hasnain; J B Sacci; B P Holloway; H Fujioka; N Kumar; R Wohlhueter; S L Hoffman; W E Collins; A A Lal
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

6.  HLA class I restriction as a possible driving force for Chikungunya evolution.

Authors:  Joo Chuan Tong; Diane Simarmata; Raymond T P Lin; Laurent Rénia; Lisa F P Ng
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

Review 7.  Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'.

Authors:  S L Takala; C V Plowe
Journal:  Parasite Immunol       Date:  2009-09       Impact factor: 2.280

8.  Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.

Authors:  Daniel Dodoo; Michael R Hollingdale; Dorothy Anum; Kwadwo A Koram; Ben Gyan; Bartholomew D Akanmori; Josephine Ocran; Susan Adu-Amankwah; Harini Geneshan; Esteban Abot; Jennylyn Legano; Glenna Banania; Renato Sayo; Donald Brambilla; Sanjai Kumar; Denise L Doolan; William O Rogers; Judith Epstein; Thomas L Richie; Martha Sedegah
Journal:  Malar J       Date:  2011-06-20       Impact factor: 2.979

9.  Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.

Authors:  Mohammad Zeeshan; Mohammad Tauqeer Alam; Sumiti Vinayak; Hema Bora; Rupesh Kumar Tyagi; Mohd Shoeb Alam; Vandana Choudhary; Pooja Mittra; Vanshika Lumb; Praveen Kumar Bharti; Venkatachalam Udhayakumar; Neeru Singh; Vidhan Jain; Pushpendra Pal Singh; Yagya Dutta Sharma
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

10.  Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.

Authors:  Stephen W Scally; Rajagopal Murugan; Alexandre Bosch; Gianna Triller; Giulia Costa; Benjamin Mordmüller; Peter G Kremsner; B Kim Lee Sim; Stephen L Hoffman; Elena A Levashina; Hedda Wardemann; Jean-Philippe Julien
Journal:  J Exp Med       Date:  2017-11-22       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.